128345-62-0

Antagonist (to histamine H2receptors).

Tritec (GlaxoSmithKline).

A poison by ingestion.

Ranitidine bismuth citrate, a novel salt formed from ranitidine and a bismuth citrate complex, is a new agent introduced in the United Kingdom for the treatment of duodenal and benign gastric ulcers, for eradication of Helicobacfer pylori, and for prevention of relapse of duodenal ulcer when administered in combination with an antibiotic such as clarithromycin or amoxicillin. Ranitidine is a potent histamine H₂-receptor antagonist with ability to inhibit gastric acid secretion. Other type of agents such as tripotassium dicitrato bismuthate exert their therapeutic effects in peptic ulceration by providing a protective coating to the ulcer crater, stimulating endogenous prostaglandin production, and inhibiting pepsin activity. More significantly, they inhibit micro-organism Helicobacfer pylori, a prevalent, specifically human pathogen associated with gastritis and gastric ulcers. The title compound possesses a novel combination of properties of the above two types of drugs and displays excellent therapeutic efficacy in clinical studies. Ranitidine bismuth citrate is being investigated for use in gastritis and non-ulcerating dyspepsia, acute healing of gastrointestinal ulcer and in prevention of the recurrence of peptic ulcer disease.

Glaxo Wellcome (United Kingdom)

Ranitidine bismuth citrate has been developed for combination therapy with antibiotics for eradication of H.p. Depending on the co-prescription, eradication ranged from 15 to 92 % in an intention-to-treat analysis . It is claimed to combine the antisecretory action of ranitidine with the antimicrobial and gastroprotective actions of bismuth.